Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.64 |
| ▸ | HPN | P05981 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.62 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.40 |
| ▸ | GLRB | P48167 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10685643 | 0.88 | HPN (0.66) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL21222730 | 0.82 | VCAM1 (0.57) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL8309788 | 0.81 | VCAM1 (0.55) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL14037559 | 0.79 | VCAM1 (0.70) | VCAM1HPNMAPTALOX15SIRT5 | |
| SCHEMBL648883 | 0.79 | VCAM1 (0.59) | VCAM1HPNMAPTALOX15SIRT5 | |
| Probucol SCHEMBL5143451 | 0.79 | HPN (1.00) | VCAM1HPNMAPTALOX15SIRT5 | |
| Probucol SCHEMBL4150 | 0.79 | HPN (1.00) | VCAM1HPNMAPTALOX15SIRT5 | |
| Elsibucol SCHEMBL6002307 | 0.78 | VCAM1 (0.73) | VCAM1HPNMAPTALOX15SIRT5 | |
| Succinobucol SCHEMBL347492 | 0.78 | VCAM1 (1.00) | VCAM1HPNMAPTALOX15SIRT5 | |
| Probucol SCHEMBL4620631 | 0.77 | ALOX15 (0.95) | VCAM1HPNMAPTALOX15SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | DEMOTECH.INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | DEMOTECH.INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | DEMOTECH.INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210040052-A1 | PROBUCOL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | DEMOTECH.INC. (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-3747863-A1 | PROBUCOL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | DEMOTECH.INC. (CN) | 2020-12-09 | — | — | EP | disclosed |
| CN-108299263-B | Probucol derivative and preparation method and application thereof | 北京德默高科医药技术有限公司 | 2020-12-01 | — | — | CN | disclosed |
| WO-2019149091-A1 | PROBUCOL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京德默高科医药技术有限公司 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040052-A1 | PROBUCOL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | PNLIP, FAR1, CETP | VCAM1 44/4885HPN 1810/4885MAPT 2720/4885 |
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | PNLIP, FAR1, CETP | VCAM1 44/4885HPN 1810/4885MAPT 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.